EWTX Quote, Financials, Valuation and Earnings

Regenxbio has a net margin of -- compared to Edgewise Therapeutics's net margin of -246.3%. Edgewise Therapeutics's return on equity of -- beat Regenxbio's return on equity of -69.62%.

Edgewise Therapeutics has a consensus price target of $49.43, signalling upside risk potential of 60.8%. On the other hand Regenxbio has an analysts' consensus of $37.64 which suggests that it could grow by 393.27%. Given that Regenxbio has higher upside potential than Edgewise Therapeutics, analysts believe Regenxbio is more attractive than Edgewise Therapeutics.

Edgewise Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regenxbio has a beta of 1.243, suggesting its more volatile than the S&P 500 by 24.251%.

Edgewise Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.

Edgewise Therapeutics quarterly revenues are --, which are smaller than Regenxbio quarterly revenues of $24.2M. Edgewise Therapeutics's net income of -$34.1M is higher than Regenxbio's net income of -$59.6M. Notably, Edgewise Therapeutics's price-to-earnings ratio is -- while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics is -- versus 4.32x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -- compared to Edgewise Therapeutics's net margin of 7.2%. Edgewise Therapeutics's return on equity of -- beat Sarepta Therapeutics's return on equity of 12.48%.

Edgewise Therapeutics has a consensus price target of $49.43, signalling upside risk potential of 60.8%. On the other hand Sarepta Therapeutics has an analysts' consensus of $185.10 which suggests that it could grow by 55.59%. Given that Edgewise Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Edgewise Therapeutics is more attractive than Sarepta Therapeutics.

Edgewise Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.767, suggesting its less volatile than the S&P 500 by 23.328%.

Edgewise Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Edgewise Therapeutics quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $467.2M. Edgewise Therapeutics's net income of -$34.1M is lower than Sarepta Therapeutics's net income of $33.6M. Notably, Edgewise Therapeutics's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 77.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics is -- versus 7.30x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Entrada Therapeutics has a net margin of -- compared to Edgewise Therapeutics's net margin of -71.7%. Edgewise Therapeutics's return on equity of -- beat Entrada Therapeutics's return on equity of 17.06%.

Edgewise Therapeutics has a consensus price target of $49.43, signalling upside risk potential of 60.8%. On the other hand Entrada Therapeutics has an analysts' consensus of -- which suggests that it could grow by 50.16%. Given that Edgewise Therapeutics has higher upside potential than Entrada Therapeutics, analysts believe Edgewise Therapeutics is more attractive than Entrada Therapeutics.

Edgewise Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Entrada Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Edgewise Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Entrada Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics pays -- of its earnings as a dividend. Entrada Therapeutics pays out -- of its earnings as a dividend.

Edgewise Therapeutics quarterly revenues are --, which are smaller than Entrada Therapeutics quarterly revenues of $19.6M. Edgewise Therapeutics's net income of -$34.1M is lower than Entrada Therapeutics's net income of -$14M. Notably, Edgewise Therapeutics's price-to-earnings ratio is -- while Entrada Therapeutics's PE ratio is 11.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics is -- versus 2.95x for Entrada Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -- compared to Edgewise Therapeutics's net margin of 37.71%. Edgewise Therapeutics's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -2.89%.

Edgewise Therapeutics has a consensus price target of $49.43, signalling upside risk potential of 60.8%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $498.37 which suggests that it could grow by 25.42%. Given that Edgewise Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Edgewise Therapeutics is more attractive than Vertex Pharmaceuticals.

Edgewise Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

Edgewise Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Edgewise Therapeutics quarterly revenues are --, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Edgewise Therapeutics's net income of -$34.1M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Edgewise Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics is -- versus 9.73x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.